An interventional study of Probiotic: Lactobacillus salivarius + Vit D + Zinc and Placebo in Covid19, sponsored by ProbiSearch SL. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-31.
Sponsored by ProbiSearch SL · Not applicable, Interventional, and Treatment
An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strain on the immune response in participants positive for SARS-CoV-2 infection.
The study duration will be 28 days, which includes 4 weeks product administration. Participants will be randomized assigned to one of the two study groups: the control group with placebo consumption and a probiotic consumption group.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 41 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ProbiSearch SL is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Lactobacillus strain during 28 days, approximately 1\*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.
Dietary Supplement: Probiotic: Lactobacillus salivarius + Vit D + Zinc
Placebo supplement in 1 capsule per day during 28 days.
Dietary Supplement: Placebo
A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
Placebo in 1 capsule will be daily administrated during 28 days.
Concentration of specific IgM (Immunoglobulin M) and IgG (Immunoglobulin G) antibodies for the SARS-CoV-2 virus.
Time frame: 1 month
Levels (pg/ml) of pro-inflammatory and anti-inflammatory markers in blood serum.
Time frame: 1 month
Duration of the symptoms produced by the SARS-CoV-2 infection
Time frame: 1 month
Severity of symptoms produced during SARS-CoV-2 infection
Severity of symtoms will be analysed for fever (Tª\>38ºC) and gastrointestinal symptons (Bristol scale).
Time frame: 1 month
Percentage of participants with a negative result in the SARS-CoV-2 detection test by PCR (Polymerase Chain Reaction) at visit 2
Time frame: 1 month
Percentage of participants with worsening of lower respiratory tract infections
Time frame: 1 month
Plan to share: No
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ProbiSearch SL